Unveiling the Targets Involved in the Quest of Antileishmanial Leads Using In silico Methods

Area of Science:

• * Parasitology
• * Drug Discovery
• * Molecular Biology

Background:

• * Leishmaniasis is a neglected tropical disease with limited treatment options due to drug toxicity and resistance.
• * Target-based drug identification is a crucial strategy for developing novel antileishmanial therapies.
• * Current research focuses on understanding the molecular mechanisms of existing antileishmanial compounds.

Purpose of the Study:

• * To identify molecular targets involved in the pharmacological action of potent antileishmanial compounds.
• * To explore potential drug targets for developing new treatments against Leishmania parasites.
• * To contribute to the development of effective therapies for leishmaniasis.

Main Methods:

• * Comprehensive literature review of molecular interactions of antileishmanial compounds.
• * Analysis of data from major scientific databases (e.g., PubMed, Scopus, Web of Science).
• * Focus on studies published within the last five years.

Main Results:

• * Several in vitro antileishmanial compounds exhibit selective interactions with key Leishmania parasite enzymes.
• * Identified targets include arginase, pteridine reductase 1, trypanothione reductase, and pyruvate kinase.
• * These enzymes are essential for the survival and virulence of the Leishmania parasite.

Conclusions:

• * In-silico analysis of small molecules can identify potential pharmacological tools for leishmaniasis treatment.
• * Understanding the multi-target action of compounds can elucidate their mechanisms of action.
• * Optimization of promising antileishmanial compounds can enhance their biological activity and therapeutic potential.